China, South Korea OK GlaxoSmithKline's $43B Covidien Buy
Chinese regulatory authorities have signed off on the planned $43 billion merger between Medtronic (NYSE:MDT) and Covidien (NYSE:COV), a major milestone as both companies push to conclude the transaction by end of the 2015 1st quarter.
The Chinese Ministry of Commerce's clearance of the massive deal comes in tandem with the South Korean Fair Trade Commission's acceptance of the M&A agreement, Medtronic said today. As well, the companies now have all necessary antitrust clearances in hand.
Help employers find you! Check out all the jobs and post your resume.
The Chinese Ministry of Commerce's clearance of the massive deal comes in tandem with the South Korean Fair Trade Commission's acceptance of the M&A agreement, Medtronic said today. As well, the companies now have all necessary antitrust clearances in hand.
Help employers find you! Check out all the jobs and post your resume.